Publication
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugSevabertinibcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 Exon 20 Insertioncivic_curation1.00
- variantERBB2 G776delinsLCcivic_curation1.00
- variantERBB2 G776delinsVCcivic_curation1.00
- variantERBB2 G778_P780dupcivic_curation1.00
- variantERBB2 Kinase Domain Mutationcivic_curation1.00
- variantERBB2 S310Fcivic_curation1.00
- variantERBB2 V659Ecivic_curation1.00
- variantERBB2 Y772_A775dupcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 41104928
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Exon 20 Insertion + ERBB2 Kinase Domain Mutation1 | ||||||||
| Sevabertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID12808In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC) PMID 41104928 · Le et al., 2025 · Open in CIViC | civic |
| ERBB2 G776delinsLC + ERBB2 G776delinsVC + ERBB2 G778_P780dup + ERBB2 S310F + ERBB2 V659E + ERBB2 Y772_A775dup1 | ||||||||
| Sevabertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12807In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC) PMID 41104928 · Le et al., 2025 · Open in CIViC | civic |